The partnership says that it will launch the drug in the European Union on or after October 16, 2018.
Today, Mylan and its partner Fujifilm Kyowa Kirin Biologics announced that the European Commission has granted marketing authorization to Hulio, the partnerships’ adalimumab biosimilar referencing Humira. The biosimilar received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for the molecule, FKB327, in July 2018.
The authorization applies to all 28 EU member states, as well as the European Economic Area states, for all indications of the reference Humira.
Mylan President Rajiv Malik commented, “We’re very pleased with the decision of the European Commission to grant marketing authorization for Hulio. This is the fourth product that Mylan will be bringing to market in the area of complex generics and biosimilars, and we’re proud to be a leader in the market formation. We’ve made great progress with Fujifilm Kyowa Kirin Biologics and look forward to continuing this important collaboration.”
The partnership says that it will launch the drug on or after October 16, 2018; in a statement, the companies revealed that Fujifilm Kyowa Kirin has obtained a nonexclusive royalty license with Humira maker, AbbVie, for the use and sale of adalimumab in Europe, and that Mylan has a sublicense. Mylan has previously announced a settlement with AbbVie that covered only Mylan’s right to market a biosimilar adalimumab in ex-European territories, including the United States, starting in July 2023.
Hulio will join a widening group of adalimumab biosimilars entering the European marketplace next month; Samsung Bioepis and Biogen stuck a deal with AbbVie in April 2018 that will allow them to launch their Imraldi on October 16, and Amgen reached a similar settlement in 2017 that will allow it to enter the market on the same date as Imraldi.
Health systems in Europe are already preparing to introduce biosimilar adalimumab and reap what they hope will be a substantial cost savings; the United Kingdom’s National Health Service, for one, has implemented a working group to provide oversight on using the best-value adalimumab using a commissioning framework that launched in 2017. The framework proposes that at least 90% of patients new to treatment and 80% of patients currently receiving treatment be prescribed the best-value biologic within 12 months of the launch of a biosimilar for a given biologic therapy.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
January 21st 2025In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab and denosumab, marking significant progress in expanding treatment options and market competition.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Senators Introduce Bipartisan Legislation to Protect Skinny Labeling
January 2nd 2025To close out the year, 4 senators came together to introduce a new bipartisan bill to protect biosimilar and generic drug manufacturers from patent litigation when obtaining “skinny label” approvals for their products.
2 Commerce Drive
Cranbury, NJ 08512